Chia-Chun Chiang, MD

Associate Professor of Neurology
Mayo Clinic

Chia-Chun Chiang, MD is an Associate Professor of Neurology, board certified Headache specialist and Stroke specialist at Mayo Clinic in Rochester, MN. Dr. Chiang completed her Neurology residency and Headache fellowship training at Mayo Clinic Arizona, where she received the Manfred D. Muenter Award for outstanding performance during residency. Dr. Chiang also completed a Vascular Neurology fellowship at the University of California, San Diego. She received her medical degree from National Yang Ming University in Taipei, Taiwan. Her current clinical and research interest is employing artificial intelligence for headache disorders, and investigating the relationship between migraine and stroke association. Dr. Chiang received many prestigious award, including the 2024 American Headache Society (AHS) Harold G Wolff Award, the 2024 American Academy Neurology Harold Wolff-John Graham Award, and the 2022 AHS Early Career Award. Dr. Chiang currently serves as the chair of the Migraine and Vascular Special Interest Group of the AHS.

Poster(s):

• (E 20) White Matter Hyperintensities in Migraine: Findings from a Mayo Clinic Cohort

• (E 29) Vascular Risk Prediction in Migraine: A Multimodality Risk Score Based on Artificial Intelligence-Electrocardiogram Output, Echocardiography, and Detailed Migraine Characteristics

• (F 02) Patterns of self-reported triggers within females and males with migraine and their association with prodromal and other migraine attack symptoms

• (F 03) Migraine aura status and patent foramen ovale – Case report

• (T 13) Blood Pressure Changes With Atogepant in Overweight and Obese Persons With Migraine and Baseline Hypertension: Interim Analysis of a Phase 3, Multicenter, Open-label, 156-Week Extension Study

• (T 19) Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM

• (T 30) Symbravo® (MoSEIC(TM) Meloxicam and Rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials

• (T 87) Prospective open-label pilot study of rimegepant as a treatment for cluster headache

• (CP 07) Natural Language Processing of Clinical Notes to Support Primary Care Diagnosis of Migraine

• (CR 20) An Unusual Cause of Severe Headache and Convexity Subarachnoid Hemorrhage